Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 10 | 2024 | 112 | 4.360 |
Why?
|
| Diabetic Nephropathies | 6 | 2023 | 38 | 2.730 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 820 | 2.680 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2024 | 6 | 2.160 |
Why?
|
| Albuminuria | 3 | 2024 | 23 | 1.940 |
Why?
|
| Kidney Failure, Chronic | 3 | 2024 | 188 | 1.810 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 671 | 1.770 |
Why?
|
| Hyponatremia | 3 | 2022 | 12 | 1.730 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 186 | 1.720 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 198 | 1.710 |
Why?
|
| Kidney | 6 | 2023 | 391 | 1.470 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 95 | 1.460 |
Why?
|
| Betacoronavirus | 3 | 2020 | 159 | 1.390 |
Why?
|
| Nutrition Surveys | 3 | 2024 | 152 | 1.290 |
Why?
|
| Pandemics | 4 | 2020 | 603 | 1.170 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 127 | 1.110 |
Why?
|
| Amyloidosis | 2 | 2024 | 58 | 1.100 |
Why?
|
| Biomarkers | 5 | 2024 | 1199 | 1.100 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2022 | 11 | 0.950 |
Why?
|
| Humans | 45 | 2024 | 58880 | 0.930 |
Why?
|
| Adiposity | 1 | 2024 | 79 | 0.920 |
Why?
|
| Creatinine | 5 | 2024 | 121 | 0.870 |
Why?
|
| Neoplasms | 3 | 2023 | 1221 | 0.870 |
Why?
|
| Water Intoxication | 1 | 2022 | 1 | 0.840 |
Why?
|
| Polydipsia, Psychogenic | 1 | 2022 | 1 | 0.840 |
Why?
|
| Resuscitation | 1 | 2023 | 67 | 0.820 |
Why?
|
| Metabolic Syndrome | 1 | 2023 | 148 | 0.810 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 257 | 0.770 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 156 | 0.760 |
Why?
|
| Naphthyridines | 1 | 2021 | 7 | 0.750 |
Why?
|
| Coronavirus | 1 | 2020 | 12 | 0.730 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 9 | 0.720 |
Why?
|
| Lactic Acid | 1 | 2020 | 70 | 0.700 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 62 | 0.680 |
Why?
|
| Renal Dialysis | 3 | 2018 | 184 | 0.670 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 141 | 0.660 |
Why?
|
| Mortality | 1 | 2020 | 158 | 0.660 |
Why?
|
| Heart Failure | 3 | 2023 | 859 | 0.630 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 62 | 0.630 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 172 | 0.630 |
Why?
|
| Adult | 15 | 2024 | 15609 | 0.600 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 531 | 0.590 |
Why?
|
| Kidney Diseases | 3 | 2024 | 157 | 0.580 |
Why?
|
| Risk Factors | 7 | 2024 | 4975 | 0.570 |
Why?
|
| Disease Progression | 6 | 2024 | 1030 | 0.540 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2020 | 40 | 0.530 |
Why?
|
| Aged | 15 | 2024 | 13221 | 0.510 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 14 | 0.490 |
Why?
|
| Hypertension | 2 | 2020 | 598 | 0.480 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 42 | 0.480 |
Why?
|
| Patient Preference | 1 | 2015 | 74 | 0.470 |
Why?
|
| Incidence | 4 | 2024 | 1226 | 0.450 |
Why?
|
| Female | 20 | 2024 | 30581 | 0.440 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.430 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 10 | 0.430 |
Why?
|
| Middle Aged | 13 | 2024 | 16134 | 0.430 |
Why?
|
| Republic of Korea | 2 | 2024 | 27 | 0.430 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 388 | 0.430 |
Why?
|
| Prognosis | 4 | 2024 | 1561 | 0.410 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 38 | 0.410 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2022 | 3 | 0.400 |
Why?
|
| Patient Safety | 1 | 2015 | 235 | 0.400 |
Why?
|
| Hyperoxaluria | 2 | 2024 | 8 | 0.400 |
Why?
|
| Male | 17 | 2024 | 27286 | 0.400 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 245 | 0.390 |
Why?
|
| Cause of Death | 2 | 2024 | 200 | 0.390 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 13 | 0.390 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 11 | 0.390 |
Why?
|
| Machine Learning | 2 | 2024 | 135 | 0.380 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 46 | 0.360 |
Why?
|
| Prospective Studies | 6 | 2024 | 3077 | 0.350 |
Why?
|
| Signal Transduction | 1 | 2020 | 2881 | 0.350 |
Why?
|
| Risk Assessment | 3 | 2024 | 1893 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2024 | 2429 | 0.330 |
Why?
|
| Pneumonia | 1 | 2011 | 263 | 0.300 |
Why?
|
| Albumins | 2 | 2024 | 32 | 0.290 |
Why?
|
| Recovery of Function | 3 | 2024 | 262 | 0.280 |
Why?
|
| Communication | 1 | 2011 | 531 | 0.270 |
Why?
|
| Aldosterone | 2 | 2022 | 15 | 0.260 |
Why?
|
| Potassium | 2 | 2022 | 109 | 0.250 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2024 | 17 | 0.240 |
Why?
|
| Nephrologists | 1 | 2024 | 6 | 0.240 |
Why?
|
| Waist Circumference | 1 | 2024 | 55 | 0.240 |
Why?
|
| Osteopontin | 1 | 2024 | 22 | 0.240 |
Why?
|
| Stroke | 2 | 2024 | 1135 | 0.240 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 16 | 0.230 |
Why?
|
| Time Factors | 2 | 2024 | 3544 | 0.230 |
Why?
|
| Device Removal | 1 | 2024 | 54 | 0.230 |
Why?
|
| Angiotensins | 2 | 2020 | 5 | 0.230 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 68 | 0.220 |
Why?
|
| Atrial Appendage | 1 | 2024 | 26 | 0.220 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 19 | 0.220 |
Why?
|
| Aphasia | 1 | 2024 | 42 | 0.220 |
Why?
|
| Cystatin C | 1 | 2023 | 7 | 0.220 |
Why?
|
| United States | 3 | 2024 | 7441 | 0.210 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 6 | 0.210 |
Why?
|
| Proteomics | 1 | 2024 | 252 | 0.210 |
Why?
|
| Fluid Therapy | 1 | 2023 | 53 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 137 | 0.210 |
Why?
|
| Canagliflozin | 1 | 2022 | 5 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.200 |
Why?
|
| India | 2 | 2024 | 156 | 0.200 |
Why?
|
| Adipose Tissue | 1 | 2024 | 283 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2024 | 890 | 0.200 |
Why?
|
| Models, Immunological | 1 | 2022 | 79 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2316 | 0.190 |
Why?
|
| Patient Selection | 1 | 2024 | 440 | 0.190 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 22 | 0.180 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2020 | 5 | 0.180 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 7 | 0.180 |
Why?
|
| Ascites | 1 | 2020 | 21 | 0.180 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.180 |
Why?
|
| Ions | 1 | 2020 | 52 | 0.180 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 89 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 701 | 0.180 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 63 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 147 | 0.180 |
Why?
|
| Diuretics | 1 | 2020 | 58 | 0.180 |
Why?
|
| Vasodilation | 1 | 2020 | 38 | 0.170 |
Why?
|
| Lung Injury | 1 | 2020 | 31 | 0.170 |
Why?
|
| Drainage | 1 | 2020 | 144 | 0.170 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 48 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 96 | 0.170 |
Why?
|
| Drug Discovery | 1 | 2020 | 91 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 137 | 0.170 |
Why?
|
| Virus Internalization | 1 | 2020 | 95 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 674 | 0.160 |
Why?
|
| Calcium | 1 | 2022 | 550 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5100 | 0.150 |
Why?
|
| Maternal Mortality | 1 | 2018 | 12 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2018 | 19 | 0.150 |
Why?
|
| Pregnancy | 2 | 2018 | 2334 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 662 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5046 | 0.140 |
Why?
|
| Gene Expression | 1 | 2020 | 804 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 362 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 855 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 187 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 794 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2444 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 981 | 0.120 |
Why?
|
| Vascular Grafting | 1 | 2015 | 36 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2012 | 249 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2015 | 102 | 0.110 |
Why?
|
| Prevalence | 1 | 2018 | 1277 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1302 | 0.110 |
Why?
|
| Infant | 1 | 2018 | 1509 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 146 | 0.110 |
Why?
|
| Patient Participation | 1 | 2015 | 208 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1441 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 244 | 0.100 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 101 | 0.100 |
Why?
|
| Oxalates | 2 | 2024 | 17 | 0.100 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2011 | 50 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 1178 | 0.090 |
Why?
|
| Child | 1 | 2020 | 4243 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1446 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 211 | 0.090 |
Why?
|
| Patients | 1 | 2011 | 102 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 295 | 0.090 |
Why?
|
| Comorbidity | 1 | 2012 | 1084 | 0.080 |
Why?
|
| Young Adult | 1 | 2018 | 4279 | 0.070 |
Why?
|
| Health Behavior | 1 | 2011 | 468 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 709 | 0.070 |
Why?
|
| Mice | 1 | 2020 | 10194 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 490 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2020 | 5922 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 738 | 0.060 |
Why?
|
| Tenascin | 1 | 2024 | 4 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2024 | 17 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 72 | 0.060 |
Why?
|
| Curcuma | 1 | 2024 | 2 | 0.060 |
Why?
|
| Aortography | 1 | 2024 | 53 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2024 | 59 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 83 | 0.060 |
Why?
|
| Embolism | 1 | 2024 | 37 | 0.060 |
Why?
|
| Urinalysis | 1 | 2023 | 33 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2024 | 201 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 109 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 37 | 0.050 |
Why?
|
| Urea | 1 | 2022 | 32 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 59 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 239 | 0.050 |
Why?
|
| Animals | 1 | 2020 | 19498 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 5871 | 0.050 |
Why?
|
| Renal Elimination | 1 | 2022 | 3 | 0.050 |
Why?
|
| Biopsy | 1 | 2023 | 372 | 0.050 |
Why?
|
| Thrombosis | 1 | 2024 | 193 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2024 | 243 | 0.050 |
Why?
|
| Phosphorus | 1 | 2020 | 17 | 0.050 |
Why?
|
| Renin | 1 | 2020 | 9 | 0.050 |
Why?
|
| Genotype | 1 | 2022 | 641 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 318 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 33 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 551 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 326 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 957 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 435 | 0.040 |
Why?
|
| Brain | 1 | 2024 | 1475 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1096 | 0.030 |
Why?
|
| Cholesterol | 1 | 2011 | 256 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 518 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 829 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 902 | 0.010 |
Why?
|